A Newly Public Biotech Bets Against the Filler

Miles Harrison and Brian Pilcher spent a recent episode of Dermatology Times' podcast "The Cutaneous Connection" making a case that the aesthetics field has been solving the wrong problem. Harrison is president and CEO of Conexeu Sciences, and Pilcher, the company's chief medical officer, laid out the pitch alongside him: dermal fillers and biostimulators correct volume and contour, but they don't rebuild the scaffold of collagen and proteins that skin actually needs to support new tissue growth. Conexeu's answer is CXU, a patented thermosensitive collagen-based extracellular matrix that goes in as a liquid and gels at body temperature within about ten minutes.

The company, which direct-listed on Nasdaq under the ticker CNXU on May 21, is still preclinical. It has completed a 12-month proof-of-concept study tracking tissue remodeling, persistence, inflammatory response, and mechanical properties, but the results remain unpublished pending peer review, a detail Harrison and Pilcher acknowledge in the transcript itself. That leaves the ECM-restoration argument as a claim to watch rather than a settled finding.

The regulatory path reflects that caution. Conexeu is pursuing a 510(k) Class II device clearance built on a predicate-based strategy, with a submission planned for early 2027, and wound care is deliberately the lead indication. Establishing the material's safety profile in wounds first, then expanding into aesthetics and other applications, is the sequencing move regenerative-medicine companies have leaned on before when introducing a genuinely new material class through a pathway designed around precedent.

The timing lines up with a shift already underway in dermatology clinics. Semaglutide- and tirzepatide-class weight-loss drugs have been linked in a run of 2025-2026 papers to what clinicians are calling "GLP-1 face," in which rapid fat loss leaves skin lax and its collagen scaffold visibly depleted, particularly around the eyes and midface. The current standard response combines hyaluronic acid filler with collagen biostimulators like poly-L-lactic acid or calcium hydroxylapatite, targeted anatomically to the areas losing structure. Conexeu is positioning CXU as a more direct fix for that same structural problem, arguing that restoring the matrix itself, rather than adding volume on top of a degraded one, is what a growing population of post-GLP-1 patients will need. Whether an unpublished proof-of-concept and a first regulatory submission still eighteen months out can catch that demand curve is the open question the podcast leaves unanswered.